+ND Capital

AIRNA is a biotechnology company specializing in the development of RNA editing therapies. Its platform enables the creation of therapeutics designed to treat both rare and common diseases, with the goal of improving patients' health.

Constructive Bio is a biotechnology company that rewrites genomes to turn living cells into biofactories for sustainable materials and therapeutics. By controlling the genetic sequence, it enables the biosynthesis of enzymes, pharmaceuticals, and biomaterials while exploring chemical space beyond natural biology. The approach includes developing virus-resistant organisms and supporting next-generation bioprocesses and biopharmaceuticals.

Vandria is a biotechnology company focused on developing mitophagy inducers aimed at rejuvenating cells to combat aging and chronic diseases. By targeting the autophagy process, Vandria's products facilitate the elimination and recycling of damaged mitochondria, which is essential for maintaining proper mitochondrial function. This innovative approach seeks to help patients mitigate the effects of age-related disorders and improve overall health. Through its research and development efforts, Vandria aims to provide effective solutions for individuals facing the challenges associated with aging and chronic health conditions.

AIRNA is a biotechnology company specializing in the development of RNA editing therapies. Its platform enables the creation of therapeutics designed to treat both rare and common diseases, with the goal of improving patients' health.

PulseSight Therapeutics is an ophthalmology-focused biotechnology company developing treatments for severe retinal diseases. It advances non-viral gene therapies delivered through minimally invasive methods to address blindness associated with retinal conditions. In addition, the company develops therapeutic proteins aimed at treating both short- and long-term retinal disorders, including chronic non-infectious uveitis, degenerative diseases, retinal vascular diseases, and macular edema. These approaches seek to improve ocular bioavailability and tolerability while supporting adherence to treatment. By focusing on therapies that preserve and improve vision, PulseSight aims to provide physicians and ophthalmologists with options that address unmet clinical needs and improve patient quality of life.

Vandria is a biotechnology company focused on developing mitophagy inducers aimed at rejuvenating cells to combat aging and chronic diseases. By targeting the autophagy process, Vandria's products facilitate the elimination and recycling of damaged mitochondria, which is essential for maintaining proper mitochondrial function. This innovative approach seeks to help patients mitigate the effects of age-related disorders and improve overall health. Through its research and development efforts, Vandria aims to provide effective solutions for individuals facing the challenges associated with aging and chronic health conditions.

Partillion Bioscience is a life science company developing a platform for functional single-cell analysis. This platform enables rapid compartmentalization and analysis of millions of single cells to probe biological functions such as secreted proteins, facilitating the development of advanced therapies for conditions like cancer, autoimmune disorders, and infectious diseases.

Notify Therapeutics is a biotechnology company focused on developing innovative therapies for infertility. Specifically, it targets the early, hormone-independent phase of egg maturation, aiming to create a first-in-class treatment for women who do not respond to standard hormone therapy. The company's approach involves utilizing drug-inducing factors that regulate the intracellular AKT pathway, facilitating ovarian follicle development. This non-hormonal treatment is particularly designed to assist women with low ovarian reserves, enhancing their chances of successful conception while minimizing the risks associated with multiple pregnancies.

H55 S.A., founded in 2015 and based in Sion, Switzerland, specializes in the development of electric propulsion systems and battery management solutions for the aviation industry. The company offers a range of certified technology solutions designed to transform air transportation into a cleaner, quieter, and more efficient mode of travel. H55’s integrated software and hardware offerings encompass the entire propulsion chain, including energy sources, energy management, propeller systems, electric motors, controllers, and pilot interfaces. By focusing on innovative electric propulsion and sensor technology, H55 aims to play a pivotal role in advancing autonomous aviation while making it more affordable and sustainable.

AIRNA is a biotechnology company specializing in the development of RNA editing therapies. Its platform enables the creation of therapeutics designed to treat both rare and common diseases, with the goal of improving patients' health.

Lightcast Discovery Limited, founded in 2019 and based in Cambridge, United Kingdom, specializes in drug discovery through advanced microfluidic technology. The company focuses on developing new therapies and innovative products by leveraging its unique platform, which allows for the precise and flexible control of thousands of droplets. This capability enables the combination of various cells, reporters, and reagents to conduct complex workflows without manual cell manipulation. By collaborating with major pharmaceutical companies and leading academic institutions, Lightcast Discovery seeks to enhance complex cell analysis and facilitate the discovery of new clinical approaches.

SPARK Microsystems is a fabless semiconductor company developing wireless transceiver technology for ultra-low power Internet of Things applications. Its patented solutions deliver higher data rates with lower power consumption and reduced latency, extending device battery life and enabling efficient wireless operation in energy-constrained environments.

Natron Energy develops sodium ion battery technologies for various industrial applications. Founded in 2012, the company specializes in stationary energy storage solutions, including UPS systems, electric vehicle charging, and grid support.

SiMa.ai is a software-centric, embedded edge machine learning system-on-chip company that develops a complete MLSoC platform combining hardware and software to enable high-performance, low-power machine learning inference on embedded edge devices. The platform supports traditional computing with ML inference, delivers push-button deployment and scaling at the edge, and adapts to various frameworks, networks, models, sensors, and modalities. It targets applications from computer vision to generative AI, offering improvements in performance and energy efficiency while enabling easy integration and secure operation for edge deployments.

Founded in 2020, Favik is a Colombian-based online platform designed to empower influencers by providing end-to-end brand creation and management services. It offers marketing, retail, technology, operations, finance, and business strategy solutions, enabling content creators to efficiently produce, manage, and deliver their branded products.

SiMa.ai is a software-centric, embedded edge machine learning system-on-chip company that develops a complete MLSoC platform combining hardware and software to enable high-performance, low-power machine learning inference on embedded edge devices. The platform supports traditional computing with ML inference, delivers push-button deployment and scaling at the edge, and adapts to various frameworks, networks, models, sensors, and modalities. It targets applications from computer vision to generative AI, offering improvements in performance and energy efficiency while enabling easy integration and secure operation for edge deployments.

Cytoki Pharma ApS is a biotechnology company based in Værløse, Denmark, founded in 2019. The company is focused on developing innovative treatments for diseases with significant unmet medical needs, particularly those related to epithelial injuries. As a pre-clinical entity, Cytoki Pharma's lead program centers on an engineered long-acting IL-22 protein, which has been licensed from a major pharmaceutical company. IL-22 plays a crucial role in the immune response, acting as a signal for tissue survival and repair following injury. By harnessing the therapeutic potential of this cytokine, Cytoki Pharma aims to create effective solutions for organ injuries and improve patient outcomes in conditions that currently lack adequate treatment options.

Icosavax develops virus-like particle (VLP) vaccines using its proprietary computational design platform. Its primary focus is creating vaccines for life-threatening respiratory diseases, with current candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Founded in 2017, the company aims to discover, develop, and commercialize vaccines against infectious diseases.

H55 S.A., founded in 2015 and based in Sion, Switzerland, specializes in the development of electric propulsion systems and battery management solutions for the aviation industry. The company offers a range of certified technology solutions designed to transform air transportation into a cleaner, quieter, and more efficient mode of travel. H55’s integrated software and hardware offerings encompass the entire propulsion chain, including energy sources, energy management, propeller systems, electric motors, controllers, and pilot interfaces. By focusing on innovative electric propulsion and sensor technology, H55 aims to play a pivotal role in advancing autonomous aviation while making it more affordable and sustainable.

Natron Energy develops sodium ion battery technologies for various industrial applications. Founded in 2012, the company specializes in stationary energy storage solutions, including UPS systems, electric vehicle charging, and grid support.

Orca Bio is a clinical-stage cell therapy company focused on providing curative treatments for patients with various malignant and autoimmune diseases. The company has developed a range of proprietary technologies aimed at replacing diseased blood and immune systems with healthy ones. By specializing in the research and development of innovative cell therapies, Orca Bio seeks to transform the landscape of bone marrow transplantation. Its advanced therapeutic platform is designed to empower healthcare professionals in effectively treating patients, thereby addressing a significant unmet medical need. The company is backed by a team of leading experts and technologists committed to realizing its vision of delivering life-saving medical solutions.

SQZ Biotech is a clinical-stage biotechnology company focused on developing innovative cell therapies for cancer, infectious diseases, and other serious health conditions. Utilizing its proprietary CellSqueeze technology, the company can deliver a variety of materials into diverse patient cell types, enabling the engineering of therapies that address a wide range of clinical challenges. SQZ Biotech aims to create well-tolerated and effective cell therapies that enhance patient experiences compared to traditional approaches. With its commitment to internal research and strategic partnerships, SQZ is working to advance a new generation of cell therapies through both immune activation and immune suppression methods, showcasing its potential to transform treatment options for patients.

SiMa.ai is a software-centric, embedded edge machine learning system-on-chip company that develops a complete MLSoC platform combining hardware and software to enable high-performance, low-power machine learning inference on embedded edge devices. The platform supports traditional computing with ML inference, delivers push-button deployment and scaling at the edge, and adapts to various frameworks, networks, models, sensors, and modalities. It targets applications from computer vision to generative AI, offering improvements in performance and energy efficiency while enabling easy integration and secure operation for edge deployments.

Arctos Medical, spun off from the University of Bern, focuses on developing innovative optogenetic therapies for treating genetic eye diseases leading to blindness. Their primary aim is to create accessible treatments for inherited retinal dystrophies (IRDs), enabling patients to potentially regain vision and improve their overall visual experience.

Icosavax develops virus-like particle (VLP) vaccines using its proprietary computational design platform. Its primary focus is creating vaccines for life-threatening respiratory diseases, with current candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Founded in 2017, the company aims to discover, develop, and commercialize vaccines against infectious diseases.

Amphivena Therapeutics, Inc. is a clinical-stage immuno-oncology company based in South San Francisco, California, dedicated to developing bifunctional antibody therapies for hematologic malignancies. Founded in 2012, the company focuses on eradicating blood cancers by leveraging the patient's immune system to target and destroy tumor cells and their precursors. Amphivena's proprietary ReSTORE platform creates dual-action biologics that not only relieve immune suppression but also activate T cell effector functions in cancer patients. This platform is designed with features such as avid binding, target selectivity, and enhanced safety, and can be further engineered to include solid tumor targeting capabilities. By offering differentiated cancer immunotherapies, Amphivena Therapeutics aims to provide new treatment options for patients who are underserved by existing immunotherapies.

Inscripta is a gene editing technology company developing scalable digital genome engineering based on CRISPR approaches. It offers MADzymes enzymes for precision editing and is building a benchtop platform comprising an instrument, consumables, software, and assays that enables automated, massively parallel, trackable editing of single cells. The platform aims to lower technical and licensing barriers, delivering push-button workflows and low-cost libraries of thousands of designer proteins, pathways, or genome variants, each with defined and trackable mutations. The company also pursues collaboration by making its MAD7 nuclease available free for research and development to broaden access and accelerate biological discovery.

Inscripta is a gene editing technology company developing scalable digital genome engineering based on CRISPR approaches. It offers MADzymes enzymes for precision editing and is building a benchtop platform comprising an instrument, consumables, software, and assays that enables automated, massively parallel, trackable editing of single cells. The platform aims to lower technical and licensing barriers, delivering push-button workflows and low-cost libraries of thousands of designer proteins, pathways, or genome variants, each with defined and trackable mutations. The company also pursues collaboration by making its MAD7 nuclease available free for research and development to broaden access and accelerate biological discovery.

SQZ Biotech is a clinical-stage biotechnology company focused on developing innovative cell therapies for cancer, infectious diseases, and other serious health conditions. Utilizing its proprietary CellSqueeze technology, the company can deliver a variety of materials into diverse patient cell types, enabling the engineering of therapies that address a wide range of clinical challenges. SQZ Biotech aims to create well-tolerated and effective cell therapies that enhance patient experiences compared to traditional approaches. With its commitment to internal research and strategic partnerships, SQZ is working to advance a new generation of cell therapies through both immune activation and immune suppression methods, showcasing its potential to transform treatment options for patients.

Serotiny, Inc. is a biotechnology company based in San Francisco, California, focused on the design and development of multi-domain proteins and therapies aimed at treating cancers and genetic disorders. Founded in 2014, Serotiny leverages a unique platform that integrates synthetic biology with advanced informatics to facilitate the rational design of proteins. The company specializes in creating therapeutic proteins for CAR T-cell therapies and other cellular therapies. By harmonizing computational protein design, high-throughput cellular assays, and next-generation sequencing, Serotiny employs a cross-disciplinary approach that incorporates expertise from immunology, machine learning, software engineering, and bioinformatics. This innovative methodology enables the development of gene and cell therapies with improved safety and efficacy through novel control mechanisms and engineered functionalities.

Inscripta is a gene editing technology company developing scalable digital genome engineering based on CRISPR approaches. It offers MADzymes enzymes for precision editing and is building a benchtop platform comprising an instrument, consumables, software, and assays that enables automated, massively parallel, trackable editing of single cells. The platform aims to lower technical and licensing barriers, delivering push-button workflows and low-cost libraries of thousands of designer proteins, pathways, or genome variants, each with defined and trackable mutations. The company also pursues collaboration by making its MAD7 nuclease available free for research and development to broaden access and accelerate biological discovery.

H55 S.A., founded in 2015 and based in Sion, Switzerland, specializes in the development of electric propulsion systems and battery management solutions for the aviation industry. The company offers a range of certified technology solutions designed to transform air transportation into a cleaner, quieter, and more efficient mode of travel. H55’s integrated software and hardware offerings encompass the entire propulsion chain, including energy sources, energy management, propeller systems, electric motors, controllers, and pilot interfaces. By focusing on innovative electric propulsion and sensor technology, H55 aims to play a pivotal role in advancing autonomous aviation while making it more affordable and sustainable.

ARMO BioSciences is a biotechnology company based in Redwood City, California, focused on developing immune modulatory biologic therapeutics. The company specializes in immuno-oncology, aiming to activate the immune system of cancer patients to recognize and eradicate tumors. Its pipeline includes several product candidates: AM0010, a long-acting form of interleukin 10 (IL-10) that stimulates the immune system; AM0001, an anti-PD-1 monoclonal antibody; AM0003, an anti-LAG-3 checkpoint inhibitor; AM0015, a form of recombinant human interleukin-15 (IL-15); and AM0012, a form of recombinant human interleukin-12 (IL-12). The company was incorporated in 2010 and formerly known as Targenics.

Inscripta is a gene editing technology company developing scalable digital genome engineering based on CRISPR approaches. It offers MADzymes enzymes for precision editing and is building a benchtop platform comprising an instrument, consumables, software, and assays that enables automated, massively parallel, trackable editing of single cells. The platform aims to lower technical and licensing barriers, delivering push-button workflows and low-cost libraries of thousands of designer proteins, pathways, or genome variants, each with defined and trackable mutations. The company also pursues collaboration by making its MAD7 nuclease available free for research and development to broaden access and accelerate biological discovery.

Tarveda Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies aimed at addressing the complexities of treating solid tumors. Founded in 2011 and based in Watertown, Massachusetts, the company specializes in miniature drug conjugates. Its lead candidate, PEN-866, utilizes a platform that targets the activated form of Heat Shock Protein 90 (HSP90) in tumors, delivering a potent topoisomerase 1 inhibitor payload, SN38. Additionally, Tarveda is evaluating another miniature drug conjugate designed for patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors, small cell lung cancer, and other solid tumors. Through its targeted approach, Tarveda seeks to extend the lives of patients facing challenging cancers while minimizing potential toxicities associated with treatment.

Emulate is a biotechnology company that develops organ-on-a-chip human emulation technology to model how diseases, medicines, chemicals, and foods affect human health. Its platform includes lung, intestinal, liver, and skin organ chips that reproduce normal biology and disease states, enabling human-relevant insights beyond traditional cell culture or animal models. The company also provides drug development tools and instrumentation software to support research and development workflows for researchers across biotechnology, pharmaceutical, consumer health, cosmetics, chemical, food, and agrochemical sectors, as well as government agencies and academic institutions. Founded in 2013 and headquartered in Boston, Emulate aims to accelerate understanding of human biology and improve human health outcomes.

SQZ Biotech is a clinical-stage biotechnology company focused on developing innovative cell therapies for cancer, infectious diseases, and other serious health conditions. Utilizing its proprietary CellSqueeze technology, the company can deliver a variety of materials into diverse patient cell types, enabling the engineering of therapies that address a wide range of clinical challenges. SQZ Biotech aims to create well-tolerated and effective cell therapies that enhance patient experiences compared to traditional approaches. With its commitment to internal research and strategic partnerships, SQZ is working to advance a new generation of cell therapies through both immune activation and immune suppression methods, showcasing its potential to transform treatment options for patients.

ARMO BioSciences is a biotechnology company based in Redwood City, California, focused on developing immune modulatory biologic therapeutics. The company specializes in immuno-oncology, aiming to activate the immune system of cancer patients to recognize and eradicate tumors. Its pipeline includes several product candidates: AM0010, a long-acting form of interleukin 10 (IL-10) that stimulates the immune system; AM0001, an anti-PD-1 monoclonal antibody; AM0003, an anti-LAG-3 checkpoint inhibitor; AM0015, a form of recombinant human interleukin-15 (IL-15); and AM0012, a form of recombinant human interleukin-12 (IL-12). The company was incorporated in 2010 and formerly known as Targenics.

Euphrates Vascular is a medical technology company based in St. Louis, Missouri, that focuses on innovative solutions for the treatment of stroke, heart disease, and other conditions. The company has developed a proprietary magnetically-enhanced diffusion (MED) system that utilizes magnet-based technology to dissolve blood clots more rapidly than existing treatment options. This system aims to improve the efficacy of FDA-approved clot-busting medications, potentially reducing mortality rates associated with stroke and cardiovascular diseases. In addition to the MED system, Euphrates Vascular offers MED MicroBeads, which are designed to deliver therapeutic agents directly to clots during thrombolysis therapy, and a touch screen-operated MED Workstation. Founded by physicists with extensive experience in medical technology, the company continues to advance its pioneering approaches in the healthcare sector, attracting interest from investors and media alike.

Founded in 2013, Twist Bioscience specializes in manufacturing and selling synthetic DNA-based products. Its innovative silicon-based DNA Synthesis Platform enables rapid, precise, high-throughput synthesis of DNA, serving customers in healthcare, agriculture, industrial chemicals, and data storage sectors.

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary platform utilizes advances in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Selecta's lead product, SEL-212, has successfully completed Phase II clinical trials for chronic refractory gout. Additionally, the company is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences has established collaborations with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development capabilities.

Crocus Technology SA specializes in the development of magnetic random access memory products and technologies tailored for the semiconductor and electronic systems industries. The company provides innovative solutions that include magnetic sensors and embedded memory technology, designed to enhance sensor data gathering and performance. Its products are utilized across various applications, including telecommunications, networking, storage, computing, and handheld devices. Crocus Technology's offerings are characterized by their ability to execute fast read and write operations within a compact footprint, which improves the performance and security of chips used in smart cards, mobile phones, and data servers. By focusing on high sensitivity, stable temperature, low power consumption, and cost-effectiveness, the company enables its clients to achieve enhanced performance and increased productivity in their operations.

Founded in 2013, Twist Bioscience specializes in manufacturing and selling synthetic DNA-based products. Its innovative silicon-based DNA Synthesis Platform enables rapid, precise, high-throughput synthesis of DNA, serving customers in healthcare, agriculture, industrial chemicals, and data storage sectors.

Tarveda Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies aimed at addressing the complexities of treating solid tumors. Founded in 2011 and based in Watertown, Massachusetts, the company specializes in miniature drug conjugates. Its lead candidate, PEN-866, utilizes a platform that targets the activated form of Heat Shock Protein 90 (HSP90) in tumors, delivering a potent topoisomerase 1 inhibitor payload, SN38. Additionally, Tarveda is evaluating another miniature drug conjugate designed for patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors, small cell lung cancer, and other solid tumors. Through its targeted approach, Tarveda seeks to extend the lives of patients facing challenging cancers while minimizing potential toxicities associated with treatment.

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary platform utilizes advances in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Selecta's lead product, SEL-212, has successfully completed Phase II clinical trials for chronic refractory gout. Additionally, the company is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences has established collaborations with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development capabilities.

Emulate is a biotechnology company that develops organ-on-a-chip human emulation technology to model how diseases, medicines, chemicals, and foods affect human health. Its platform includes lung, intestinal, liver, and skin organ chips that reproduce normal biology and disease states, enabling human-relevant insights beyond traditional cell culture or animal models. The company also provides drug development tools and instrumentation software to support research and development workflows for researchers across biotechnology, pharmaceutical, consumer health, cosmetics, chemical, food, and agrochemical sectors, as well as government agencies and academic institutions. Founded in 2013 and headquartered in Boston, Emulate aims to accelerate understanding of human biology and improve human health outcomes.

ARMO BioSciences is a biotechnology company based in Redwood City, California, focused on developing immune modulatory biologic therapeutics. The company specializes in immuno-oncology, aiming to activate the immune system of cancer patients to recognize and eradicate tumors. Its pipeline includes several product candidates: AM0010, a long-acting form of interleukin 10 (IL-10) that stimulates the immune system; AM0001, an anti-PD-1 monoclonal antibody; AM0003, an anti-LAG-3 checkpoint inhibitor; AM0015, a form of recombinant human interleukin-15 (IL-15); and AM0012, a form of recombinant human interleukin-12 (IL-12). The company was incorporated in 2010 and formerly known as Targenics.

Founded in 2013, Twist Bioscience specializes in manufacturing and selling synthetic DNA-based products. Its innovative silicon-based DNA Synthesis Platform enables rapid, precise, high-throughput synthesis of DNA, serving customers in healthcare, agriculture, industrial chemicals, and data storage sectors.

Tarveda Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies aimed at addressing the complexities of treating solid tumors. Founded in 2011 and based in Watertown, Massachusetts, the company specializes in miniature drug conjugates. Its lead candidate, PEN-866, utilizes a platform that targets the activated form of Heat Shock Protein 90 (HSP90) in tumors, delivering a potent topoisomerase 1 inhibitor payload, SN38. Additionally, Tarveda is evaluating another miniature drug conjugate designed for patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors, small cell lung cancer, and other solid tumors. Through its targeted approach, Tarveda seeks to extend the lives of patients facing challenging cancers while minimizing potential toxicities associated with treatment.

View, Inc., established in 2006 and headquartered in Milpitas, California, specializes in designing and manufacturing intelligent glass systems for various sectors, including workplace, healthcare, education, and hospitality. The company's flagship product, View Smart Windows, employs AI to automatically adjust in response to sunlight, enhancing natural light access and occupant experience, while minimizing heat and glare, and reducing energy consumption. Each View installation also includes a cloud-connected smart building platform, enabling further building optimization. With operations in the U.S. and internationally, View has improved over 90 million square feet of buildings, ranging from offices to multifamily residences.

Crocus Technology SA specializes in the development of magnetic random access memory products and technologies tailored for the semiconductor and electronic systems industries. The company provides innovative solutions that include magnetic sensors and embedded memory technology, designed to enhance sensor data gathering and performance. Its products are utilized across various applications, including telecommunications, networking, storage, computing, and handheld devices. Crocus Technology's offerings are characterized by their ability to execute fast read and write operations within a compact footprint, which improves the performance and security of chips used in smart cards, mobile phones, and data servers. By focusing on high sensitivity, stable temperature, low power consumption, and cost-effectiveness, the company enables its clients to achieve enhanced performance and increased productivity in their operations.

View, Inc., established in 2006 and headquartered in Milpitas, California, specializes in designing and manufacturing intelligent glass systems for various sectors, including workplace, healthcare, education, and hospitality. The company's flagship product, View Smart Windows, employs AI to automatically adjust in response to sunlight, enhancing natural light access and occupant experience, while minimizing heat and glare, and reducing energy consumption. Each View installation also includes a cloud-connected smart building platform, enabling further building optimization. With operations in the U.S. and internationally, View has improved over 90 million square feet of buildings, ranging from offices to multifamily residences.

Tarveda Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies aimed at addressing the complexities of treating solid tumors. Founded in 2011 and based in Watertown, Massachusetts, the company specializes in miniature drug conjugates. Its lead candidate, PEN-866, utilizes a platform that targets the activated form of Heat Shock Protein 90 (HSP90) in tumors, delivering a potent topoisomerase 1 inhibitor payload, SN38. Additionally, Tarveda is evaluating another miniature drug conjugate designed for patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors, small cell lung cancer, and other solid tumors. Through its targeted approach, Tarveda seeks to extend the lives of patients facing challenging cancers while minimizing potential toxicities associated with treatment.

View, Inc., established in 2006 and headquartered in Milpitas, California, specializes in designing and manufacturing intelligent glass systems for various sectors, including workplace, healthcare, education, and hospitality. The company's flagship product, View Smart Windows, employs AI to automatically adjust in response to sunlight, enhancing natural light access and occupant experience, while minimizing heat and glare, and reducing energy consumption. Each View installation also includes a cloud-connected smart building platform, enabling further building optimization. With operations in the U.S. and internationally, View has improved over 90 million square feet of buildings, ranging from offices to multifamily residences.

BIND Therapeutics is a clinical-stage nanomedicine platform company focused on developing innovative targeted and programmable therapeutics known as Accurins. These specialized drug delivery systems are engineered with distinct physical and chemical properties to effectively target specific cells or tissues, concentrating therapeutic agents at the disease site to improve treatment efficacy while reducing adverse effects on healthy tissues. BIND's primary focus is on oncology, with its lead drug candidate, BIND-014, currently undergoing Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. The company also collaborates with leading biopharmaceutical firms, such as Amgen, Pfizer, and AstraZeneca, to create Accurins utilizing their therapeutic payloads. Through its medicinal nanoengineering platform, BIND Therapeutics aims to advance its own pipeline and forge strategic partnerships in the field of cancer treatment.

Crocus Technology SA specializes in the development of magnetic random access memory products and technologies tailored for the semiconductor and electronic systems industries. The company provides innovative solutions that include magnetic sensors and embedded memory technology, designed to enhance sensor data gathering and performance. Its products are utilized across various applications, including telecommunications, networking, storage, computing, and handheld devices. Crocus Technology's offerings are characterized by their ability to execute fast read and write operations within a compact footprint, which improves the performance and security of chips used in smart cards, mobile phones, and data servers. By focusing on high sensitivity, stable temperature, low power consumption, and cost-effectiveness, the company enables its clients to achieve enhanced performance and increased productivity in their operations.

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary platform utilizes advances in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Selecta's lead product, SEL-212, has successfully completed Phase II clinical trials for chronic refractory gout. Additionally, the company is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences has established collaborations with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development capabilities.

SBA Materials, Inc. is a company focused on the development and commercialization of advanced electronic materials specifically for back-end line and packaging applications in semiconductor manufacturing. Founded in 2001 and based in Albuquerque, New Mexico, the company specializes in low-k dielectric materials for interlayer dielectric applications, addressing critical needs in the semiconductor industry. Its product portfolio includes uLK22, uLK1X, optical films, and various nano-porous and meso-porous materials. These materials are designed with exceptional surface areas and can be chemically functionalized, enabling a broad range of applications from electronics to optics and sensors. The company operates from a facility within the Science and Technology Park, which houses research and development laboratories, offices, and meeting spaces, fostering innovation and collaboration with local institutions, including the University of New Mexico and Sandia National Laboratories.

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary platform utilizes advances in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Selecta's lead product, SEL-212, has successfully completed Phase II clinical trials for chronic refractory gout. Additionally, the company is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences has established collaborations with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development capabilities.

Crocus Technology SA specializes in the development of magnetic random access memory products and technologies tailored for the semiconductor and electronic systems industries. The company provides innovative solutions that include magnetic sensors and embedded memory technology, designed to enhance sensor data gathering and performance. Its products are utilized across various applications, including telecommunications, networking, storage, computing, and handheld devices. Crocus Technology's offerings are characterized by their ability to execute fast read and write operations within a compact footprint, which improves the performance and security of chips used in smart cards, mobile phones, and data servers. By focusing on high sensitivity, stable temperature, low power consumption, and cost-effectiveness, the company enables its clients to achieve enhanced performance and increased productivity in their operations.

Xtellus, Inc. specializes in the development of passive optical components designed for agile optical networking systems. The company offers a range of products, including wavelength selective switches, wavelength blockers, edge wavelength selective switches, and reconfigurable optical add/drop multiplexers (ROADM) with integrated power monitoring, as well as multiplexers and demultiplexers. Additionally, Xtellus provides liquid crystal optical processors, enabling efficient management of optical signals in various networking applications. Founded in 2000 and headquartered in Morris Plains, New Jersey, Xtellus maintains manufacturing and development facilities in Israel and South Korea, along with a research and development center in Jerusalem. As of December 2009, Xtellus operates as a subsidiary of Oclaro, Inc.

BIND Therapeutics is a clinical-stage nanomedicine platform company focused on developing innovative targeted and programmable therapeutics known as Accurins. These specialized drug delivery systems are engineered with distinct physical and chemical properties to effectively target specific cells or tissues, concentrating therapeutic agents at the disease site to improve treatment efficacy while reducing adverse effects on healthy tissues. BIND's primary focus is on oncology, with its lead drug candidate, BIND-014, currently undergoing Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. The company also collaborates with leading biopharmaceutical firms, such as Amgen, Pfizer, and AstraZeneca, to create Accurins utilizing their therapeutic payloads. Through its medicinal nanoengineering platform, BIND Therapeutics aims to advance its own pipeline and forge strategic partnerships in the field of cancer treatment.

HAYA Therapeutics develops RNA-based therapeutics focused on treating fibrotic diseases. Its precision medicines target specific regulators of fibrosis in tissues like the heart, aiming to block fibrosis progression and treat associated conditions safely and effectively.